A Medical Device Daily

Pulmonx (Palo Alto, California) a company focused on advancing therapies for patients with emphysema, reported that it has acquired all of the assets of Emphasys Medical (Redwood City, California) including its endobronchial valve (EBV) technology platform and associated intellectual property.

Pulmonx has now assumed global sales, marketing, customer support, and future development programs of the Emphasys EBV (formerly known as Zephyr EBV).

"This acquisition provides Pulmonx with a strengthened ability to deliver innovative therapeutic solutions to emphysema patients and their physicians," said Niyazi Beyhan, executive VP and general manager of Pulmonx. "Our ongoing pre-clinical and clinical research programs provide encouraging evidence that the combined offering of the Emphasys EBV and our Chartis System will deliver a promising solution for endobronchial lung volume reduction (ELVR) that includes an effective assessment tool to optimize patient selection and outcomes."

Treatment of emphysema by ELVR using the Emphasys EBV has been shown in the Endobronchial Valve for Emphysema PalliatioN Trial, known as VENT, to improve lung function, exercise tolerance and quality of life for some patients.

More recent research suggests that inter-lobar collateral flow in the lungs, known as collateral ventilation, can limit the effectiveness of ELVR. Pulmonx has developed its Chartis System to identify the presence of collateral ventilation in the lungs. This may enable physicians to better identify patients who could benefit from ELVR and also confirm the effectiveness of valve placement by measuring air flow following EBV deployment.

Earlier this year, Pulmonx submitted an application to the FDA to market the Chartis System. The company hopes to receive its 510(k) clearance and begin marketing in the fall of 2009. Additionally, a CE-mark application has been submitted and the company expects to launch the Chartis System in Europe by the end of 2009.

In other dealmaking activity, Beckman Coulter (Fullerton, California) a developer of products that simplify, automate, and innovate complex biomedical testing, reported that the Federal Trade Commission has terminated its review under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, of the company's pending acquisition of Olympus' (Center Valley, Pennsylvania) lab-based diagnostics business.

As previously stated on Feb. 27, Beckman Coulter and Olympus said they had entered into a definitive agreement under which Beckman Coulter will acquire the diagnostic systems portion of Olympus' Life Sciences business for nearly $780 million.

This transaction is expected to close in 3Q09 and is subject to certain government approvals outside the U.S., the negotiation of certain ancillary agreements, the delivery of and agreement to disclosure schedules and transition arrangements as well as other customary conditions.